Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/123488
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Standard requirement of a microbiological quality control program for the manufacture of human mesenchymal stem cells for clinical use |
Autor: | Gálvez Martín, Patricia CSIC ORCID; Clares Naveros, Beatriz; Bermejo González, María CSIC ORCID; Hmadcha, Abdelkrim CSIC ORCID; Soria Escoms, Bernat CSIC ORCID | Fecha de publicación: | 13-ene-2014 | Editor: | Mary Ann Liebert | Citación: | Stem Cells and Development 23(10): 1074-1083 (2014) | Resumen: | The manufacturing of human mesenchymal stem cells (hMSCs) as cell-based products for clinical use should be performed with appropriate controls that ensure its safety and quality. The use of hMSCs in cell therapy has increased considerably in the past few years. In line with this, the assessment and management of contamination risks by microbial agents that could affect the quality of cells and the safety of patients have to be considered. It is necessary to implant a quality control program (QCP) covering the entire procedure of the ex vivo expansion, from the source of cells, starting materials, and reagents, such as intermediate products, to the final cellular medicine. We defined a QCP to detect microbiological contamination during manufacturing of autologous hMSCs for clinical application. The methods used include sterility test, Gram stain, detection of mycoplasma, endotoxin assay, and microbiological monitoring in process according to the European Pharmacopoeia (Ph. Eur.) and each analytical technique was validated in accordance with three different cell cultures. Results showed no microbiological contamination in any phases of the cultures, meeting all the acceptance criteria for sterility test, detection of mycoplasma and endotoxin, and environmental and staff monitoring. Each analytical technique was validated demonstrating the sensitivity, limit of detection, and robustness of the method. The quality and safety of MSCs must be controlled to ensure their final use in patients. The evaluation of the proposed QCP revealed satisfactory results in order to standardize this procedure for clinical use of cells. © Copyright 2014, Mary Ann Liebert, Inc. 2014. | Versión del editor: | http://dx.doi.org/10.1089/scd.2013.0625 | URI: | http://hdl.handle.net/10261/123488 | DOI: | 10.1089/scd.2013.0625 | Identificadores: | issn: 1557-8534 |
Aparece en las colecciones: | (CABIMER) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Standard Requirements.pdf | 274,68 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
15
checked on 19-abr-2024
SCOPUSTM
Citations
29
checked on 15-abr-2024
WEB OF SCIENCETM
Citations
25
checked on 23-feb-2024
Page view(s)
286
checked on 23-abr-2024
Download(s)
385
checked on 23-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.